Pembrolizumab Prolongs Recurrence-Free Survival Compared With Placebo in Stage II Resected High-Risk Melanoma

Pembrolizumab Prolongs Recurrence-Free Survival Compared With Placebo in Stage II Resected High-Risk Melanoma

Publication date: Aug 06, 2021

Reference: Merck’s’ Keytruda (pembrolizumab) significantly prolonged recurrence-free survival (RFS) compared to placebo as adjuvant therapy for patients with stage II resected high-risk melanoma in phase 3 KEYNPTE-716 trial. The KEYNOTE-716 trial, which investigated the safety and efficacy of pembrolizumab for patients with surgically resected high-risk stage II melanoma, enrolled 954 patients who were 12 years or older. Patients were only eligible for the second part of the study if they had recurrence after receiving the placebo or completed 17 cycles of pembrolizumab. Patients in the pembrolizumab group who experienced disease recurrence within 6 months of completing the treatment were excluded from part 2 of the study. Pediatric patients were to receive either pembrolizumab or the placebo intravenously up to 200 mg every 3 weeks for up to 17 cycles. -Many patients with stage II melanoma have a high risk of their cancer returning after surgery. In the first part of the double-blind study adults in the pembrolizumab group received 200 mg intravenously every 3 weeks for up to 17 cycles.

Concepts Keywords
August Nivolumab
Immunotherapeutics Adjuvant therapy
Keynote Pembrolizumab
Nct03553836 Melanoma
Cancer immunotherapy
Antineoplastic drugs
Orphan drugs
Breakthrough therapy
Clinical medicine
Cancer treatments

Semantics

Type Source Name
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH Recurrence
drug DRUGBANK Pembrolizumab
disease MESH Drug User
disease MESH metastasis
disease MESH development
disease MESH community
disease MESH cancer
pathway REACTOME Release

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *